These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35695279)

  • 21. Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series.
    Payette O; Lespérance P; Desbeaumes Jodoin V; Longpré-Poirier C; Elkrief L; Richard M; Garel N; Miron JP
    J Affect Disord; 2023 Jul; 333():18-20. PubMed ID: 37075822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.
    McIntyre RS; Rodrigues NB; Lipsitz O; Lee Y; Cha DS; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Ho R; Mansur RB; Rosenblat JD
    J Affect Disord; 2021 Jun; 288():210-216. PubMed ID: 33965843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guidance on the conversion of the Chinese versions of the Quick Inventory of Depressive Symptomatology-Self-Report (C-QIDS-SR) and the Montgomery-Asberg Scale (C-MADRS) in Chinese patients with major depression.
    Liu J; Xiang YT; Lei H; Wang Q; Wang G; Ungvari GS; Morris DW; Zhu XZ; Lai KY; Zhong BL; Wong SY; Zhang L; Zhang Q; Zou YC; Xiao L; Zhao Q; Li Y; Wu J; Zhang GF; Chiu HF
    J Affect Disord; 2014 Jan; 152-154():530-3. PubMed ID: 24144585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
    aan het Rot M; Collins KA; Murrough JW; Perez AM; Reich DL; Charney DS; Mathew SJ
    Biol Psychiatry; 2010 Jan; 67(2):139-45. PubMed ID: 19897179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
    Singh JB; Fedgchin M; Daly EJ; De Boer P; Cooper K; Lim P; Pinter C; Murrough JW; Sanacora G; Shelton RC; Kurian B; Winokur A; Fava M; Manji H; Drevets WC; Van Nueten L
    Am J Psychiatry; 2016 Aug; 173(8):816-26. PubMed ID: 27056608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct trajectories of antidepressant response to intravenous ketamine.
    O'Brien B; Lijffijt M; Lee J; Kim YS; Wells A; Murphy N; Ramakrishnan N; Swann AC; Mathew SJ
    J Affect Disord; 2021 May; 286():320-329. PubMed ID: 33770540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
    McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
    Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
    Danayan K; Chisamore N; Rodrigues NB; Vincenzo JDD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; Teopiz KM; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2023 May; 323():115133. PubMed ID: 36889160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
    Bottemanne H; Morlaas O; Claret A; Sharot T; Fossati P; Schmidt L
    JAMA Psychiatry; 2022 Nov; 79(11):1124-1132. PubMed ID: 36169969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.
    Domany Y; Bleich-Cohen M; Tarrasch R; Meidan R; Litvak-Lazar O; Stoppleman N; Schreiber S; Bloch M; Hendler T; Sharon H
    Br J Psychiatry; 2019 Jan; 214(1):20-26. PubMed ID: 30246667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Subramaniapillai M; Kratiuk K; Majeed A; Nasri F; Gill H; Mansur RB; Rosenblat JD
    Psychiatry Res; 2021 Jun; 300():113860. PubMed ID: 33836470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
    Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
    J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting.
    Sinyor M; Williams M; Belo S; Orser B; Vincent M; Mah L; Zarate C; Castel S; Levitt AJ; Schaffer A
    J Affect Disord; 2018 Dec; 241():103-109. PubMed ID: 30107350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
    Wan LB; Levitch CF; Perez AM; Brallier JW; Iosifescu DV; Chang LC; Foulkes A; Mathew SJ; Charney DS; Murrough JW
    J Clin Psychiatry; 2015 Mar; 76(3):247-52. PubMed ID: 25271445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.